Document is current
Any future updates will be listed below
-
Authors
Baker, Gregory J. https://orcid.org/0000-0002-5196-3961
Novikov, Edward
Zhao, Ziyuan
Vallius, Tuulia https://orcid.org/0000-0002-3006-4887
Davis, Janae A.
Lin, Jia-Ren https://orcid.org/0000-0003-4702-7705
Muhlich, Jeremy L. https://orcid.org/0000-0002-0811-637X
Mittendorf, Elizabeth A.
Santagata, Sandro https://orcid.org/0000-0002-7528-9668
Guerriero, Jennifer L. https://orcid.org/0000-0002-2104-5457
Sorger, Peter K. https://orcid.org/0000-0002-3364-1838
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (INV-027106)
Division of Cancer Prevention, National Cancer Institute (U2C-CA233262, U01-CA284207)
- License Information
-
More Information
Article History
Received: 31 October 2023
Accepted: 28 May 2024
First Online: 30 October 2024
Competing interests
: P.K.S. is a cofounder and member of the Board of Directors of Glencoe Software, a member of the Board of Directors for Applied Biomath and a member of the Scientific Advisory Board for RareCyte, NanoString and Montai Health; he holds equity in Glencoe and RareCyte. P.K.S. is a consultant for Merck and declares that none of these relationships has influenced the content of this manuscript. E.A.M. reports compensated service on Scientific Advisory Boards for AstraZeneca, BioNTech and Merck; uncompensated service on Steering Committees for Bristol Myers Squibb and Roche/Genentech; speakers’ honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche/Genentech (via an SU2C grant) and Gilead. She also reports research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. J.L.G. serves or has previously served on advisory boards and/or as a scientific advisory board member for Array BioPharma/Pfizer, AstraZeneca, BD Biosciences, Carisma, Codagenix, Duke Street Bio, GlaxoSmithKline, Kowa, Kymera, OncoOne and Verseau Therapeutics and has research grants from Array BioPharma/Pfizer, Duke Street Bio, Eli Lilly, GlaxoSmithKline and Merck. The other authors declare no competing interests.
